4D Molecular Therapeutics Inc (FDMT)

NASDAQ
24.74
-0.61(-2.41%)
After Hours
24.74
0.00(0.00%)
- Real-time Data
  • Volume:
    202,376
  • Bid/Ask:
    18.71/27.75
  • Day's Range:
    23.83 - 25.09

FDMT Overview

Prev. Close
24.74
Day's Range
23.83-25.09
Revenue
30.2M
Open
24.93
52 wk Range
23.84-54.98
EPS
-
Volume
202,376
Market Cap
661.69M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
140,903
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
26,745,774
Next Earnings Date
Sep 01, 2021
What is your sentiment on 4D Molecular Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

4D Molecular Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellBuy
SummaryBuyBuyStrong SellStrong SellNeutral

4D Molecular Therapeutics Inc Company Profile

4D Molecular Therapeutics Inc Company Profile

Employees
88

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.